Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report
This study shows metastatic lung adenocarcinoma with BRCA2 mutation could also respond well to PARP inhibitor, broadening the spectrum of BRCA-mutated cancers suitable for olaparib therapy. With acquired resistance to chemotherapy, bevacizumab, and immunotherapy, the patient still gained significant benefits from the targeted therapy.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
More News: Abraxane | Adenocarcinoma | Alimta | Avastin | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Immunotherapy | Lung Cancer | Oral Cancer | Ovarian Cancer | Ovaries | Smokers | Study